Resource consumption and patient employability during systemic therapy and biological therapy
Open Access
- 24 April 2021
- journal article
- Published by Publishing House OKI in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
- Vol. 20 (1), 46-55
- https://doi.org/10.37489/2588-0519-2021-1-46-54
Abstract
An important aspect of the treatment of patients with psoriasis and psoriatic arthritis is the cost of the applied methods of therapy, the costs of the healthcare system associated with the treatment of such patients, and the effect of the disease on the ability to work. The costs of the health care system are the most important component of assessing the use of various methods of therapy and are characterized not only by the financial side, but also by the assessment of the workload of medical organizations and the health care system in general.Research results.During this program, it was found that the use of GIBP is associated with a decrease in the average duration of one hospitalization case: this indicator was 2.07 days, while in patients on other types of therapy it reached an average of 10.01 days. In patients receiving other types of therapy, the average number of hospitalizations in a round-the-clock hospital was significantly higher and amounted to 0.53 compared with the GAI — the indicator corresponded to 0.10. In addition, patients on the BAU were less likely to seek outpatient care and received fewer sick leaves, which were characterized by a shorter duration.Conclusions.The use of GIBP reduces the burden on the dermatological and rheumatological service, reduces the duration of hospitalizations, and significantly improves the socio-economic situation of patients due to a more significant preservation of their ability to work.Keywords
This publication has 20 references indexed in Scilit:
- Assessment of organization of medical care and drug provision for patients with rheumatic diseases, and the socioeconomic burden of these diseases in the Russian FederationModern Rheumatology Journal, 2018
- Shifting the focus – the primary role of IL‐23 in psoriasis and other inflammatory disordersJournal of the European Academy of Dermatology and Venereology, 2018
- PSORIATIC ARTHRITIS: CLASSIFICATION, CLINICAL PRESENTATION, DIAGNOSIS, TREATMENTRheumatology Science and Practice, 2018
- The role of IL‐23 and the IL‐23/TH17 immune axis in the pathogenesis and treatment of psoriasisJournal of the European Academy of Dermatology and Venereology, 2017
- Consensus document on the evaluation and treatment of moderate‐to‐severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and VenereologyJournal of the European Academy of Dermatology and Venereology, 2016
- Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic ArthritisArthritis & Rheumatology, 2016
- INCIDENCE OF PSORIATIC ARTHRITIS IN RUSSIA: TRENDS AT THE PRESENT STAGE AND PROSPECTSRheumatology Science and Practice, 2015
- Think beyond the SkinJournal of Cutaneous Medicine and Surgery, 2015
- Definition of treatment goals for moderate to severe psoriasis: a European consensusArchiv für dermatologische Forschung, 2010
- European S3‐Guidelines on the systemic treatment of psoriasis vulgarisJournal of the European Academy of Dermatology and Venereology, 2009